MX349119B - Vacuna de virus de dengue inactivado. - Google Patents
Vacuna de virus de dengue inactivado.Info
- Publication number
- MX349119B MX349119B MX2013013862A MX2013013862A MX349119B MX 349119 B MX349119 B MX 349119B MX 2013013862 A MX2013013862 A MX 2013013862A MX 2013013862 A MX2013013862 A MX 2013013862A MX 349119 B MX349119 B MX 349119B
- Authority
- MX
- Mexico
- Prior art keywords
- dengue virus
- virus vaccine
- inactivated dengue
- inactivated
- producing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490205P | 2011-05-26 | 2011-05-26 | |
| US201161570966P | 2011-12-15 | 2011-12-15 | |
| PCT/EP2012/059879 WO2012160199A1 (en) | 2011-05-26 | 2012-05-25 | Inactivated dengue virus vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013013862A MX2013013862A (es) | 2014-01-23 |
| MX349119B true MX349119B (es) | 2017-07-12 |
Family
ID=46148894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013013862A MX349119B (es) | 2011-05-26 | 2012-05-25 | Vacuna de virus de dengue inactivado. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20140112953A1 (https=) |
| EP (1) | EP2714076A1 (https=) |
| JP (1) | JP2014515367A (https=) |
| KR (1) | KR20140033171A (https=) |
| CN (2) | CN107050445A (https=) |
| AU (2) | AU2012260807B2 (https=) |
| BR (1) | BR112013030236A2 (https=) |
| CA (1) | CA2837145A1 (https=) |
| CO (1) | CO6811814A2 (https=) |
| EA (1) | EA201391515A1 (https=) |
| IL (1) | IL229307A0 (https=) |
| MX (1) | MX349119B (https=) |
| PE (1) | PE20140646A1 (https=) |
| PH (1) | PH12013502442A1 (https=) |
| SG (1) | SG194950A1 (https=) |
| WO (1) | WO2012160199A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6781508B2 (ja) | 2014-11-18 | 2020-11-04 | 塩野義製薬株式会社 | 安定化されたペプチド組成物 |
| WO2016145149A1 (en) * | 2015-03-11 | 2016-09-15 | The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research | Combination purified inactivated vaccine for flaviviruses |
| CN107921063A (zh) | 2015-07-02 | 2018-04-17 | 普莱瓦克斯免疫肿瘤学公司 | 用于采用登革病毒与树突细胞的联合疗法的组合物及方法 |
| CN108291205A (zh) | 2015-09-26 | 2018-07-17 | 普莱瓦克斯免疫肿瘤学公司 | 用于产生树突细胞的组合物和方法 |
| GB201522068D0 (en) | 2015-12-15 | 2016-01-27 | Glaxosmithkline Biolog Sa | Dried composition |
| WO2017109698A1 (en) | 2015-12-22 | 2017-06-29 | Glaxosmithkline Biologicals Sa | Immunogenic formulation |
| WO2017210215A1 (en) * | 2016-05-31 | 2017-12-07 | The Government Of The United States Of America As Represented By The Secretary Of The Army | Zika virus vaccine and methods of production |
| JP2020500847A (ja) | 2016-11-16 | 2020-01-16 | プライムヴァックス イミュノ−オンコロジー，インク． | 癌の処置のための併用免疫療法 |
| EP3565567A4 (en) | 2017-01-04 | 2020-07-29 | Primevax Immuno-Oncology, Inc. | COMPOSITIONS AND METHODS OF THERAPY WITH DENGUE VIRUS |
| CN107140625A (zh) * | 2017-06-14 | 2017-09-08 | 中国海洋大学 | 一种利用植物油制备石墨烯薄膜的方法 |
| MX2020004151A (es) | 2017-10-30 | 2020-08-13 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos. |
| MX2020004543A (es) | 2017-11-03 | 2020-09-18 | Takeda Vaccines Inc | Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan. |
| CN116983398A (zh) | 2017-11-30 | 2023-11-03 | 武田疫苗股份有限公司 | 寨卡疫苗和免疫原性组合物以及其使用方法 |
| WO2019112921A1 (en) | 2017-12-07 | 2019-06-13 | Merck Sharp & Dohme Corp. | Formulations of dengue virus vaccine compositions |
| KR20220141280A (ko) * | 2019-12-11 | 2022-10-19 | 엔이1 인코퍼레이티드 | 암 면역요법을 위한 개인맞춤형 종양 백신 및 이의 용도 |
| EP4110381A1 (en) * | 2020-02-27 | 2023-01-04 | Takeda Vaccines, Inc. | Method for removing host cell dna from virus preparation |
| CN112546213A (zh) * | 2020-12-31 | 2021-03-26 | 中国医学科学院医学生物学研究所 | 一种制备新型冠状病毒疫苗的方法及针对其有效性的评价方法 |
| CN113750228B (zh) * | 2021-09-25 | 2024-02-20 | 大连理工大学 | 一种冷冻保护剂在铝佐剂中的应用 |
| CN115531529A (zh) * | 2022-09-16 | 2022-12-30 | 大连理工大学 | 一种冻干保护剂在含铝佐剂中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6254873B1 (en) * | 1995-04-17 | 2001-07-03 | The United States Of America As Represented By The Secretary Of The Army | Inactivated dengue virus vaccine |
| KR20030055275A (ko) * | 2000-10-02 | 2003-07-02 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 분할 외피 바이러스 제조물 |
| RU2358763C2 (ru) * | 2003-02-10 | 2009-06-20 | Элан Фармасьютикалз, Инк. | Композиции иммуноглобулина и способ их получения |
| US20090104226A1 (en) * | 2004-05-21 | 2009-04-23 | Novartis Vaccines And Diagnostics Inc. | Alphavirus Vectors for Respiratory Pathogen Vaccines |
| CN101360821A (zh) * | 2005-11-21 | 2009-02-04 | 圣诺菲·帕斯图尔有限公司 | 重组病毒的稳定制剂 |
| EP2940129B1 (en) * | 2007-04-06 | 2020-05-06 | Takeda Vaccines, Inc. | Methods and compositions for live attenuated viruses |
| JP5676452B2 (ja) * | 2008-09-29 | 2015-02-25 | カディラ ファーマシューティカルズ リミテッド | ワクチンアジュバント |
| AR075437A1 (es) * | 2009-02-17 | 2011-03-30 | Glaxosmithkline Biolog Sa | Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio, metodo para producir dicha vacuna y su uso para preparar un medicamento |
| US9005633B2 (en) * | 2009-07-17 | 2015-04-14 | The United States Of America As Represented By The Secretary Of The Navy. | Psoralen-inactivated viral vaccine and method of preparation |
| US8557253B2 (en) * | 2009-10-07 | 2013-10-15 | Sanofi Pasteur Sa | Stabilizing excipient for inactivated whole virus vaccine |
-
2012
- 2012-05-25 EA EA201391515A patent/EA201391515A1/ru unknown
- 2012-05-25 SG SG2013084298A patent/SG194950A1/en unknown
- 2012-05-25 EP EP12723216.3A patent/EP2714076A1/en not_active Withdrawn
- 2012-05-25 AU AU2012260807A patent/AU2012260807B2/en not_active Ceased
- 2012-05-25 CN CN201710173241.XA patent/CN107050445A/zh active Pending
- 2012-05-25 JP JP2014511908A patent/JP2014515367A/ja active Pending
- 2012-05-25 MX MX2013013862A patent/MX349119B/es active IP Right Grant
- 2012-05-25 CA CA2837145A patent/CA2837145A1/en not_active Abandoned
- 2012-05-25 BR BR112013030236A patent/BR112013030236A2/pt not_active Application Discontinuation
- 2012-05-25 KR KR1020137034545A patent/KR20140033171A/ko not_active Ceased
- 2012-05-25 PE PE2013002709A patent/PE20140646A1/es not_active Application Discontinuation
- 2012-05-25 WO PCT/EP2012/059879 patent/WO2012160199A1/en not_active Ceased
- 2012-05-25 CN CN201280031821.0A patent/CN103619349A/zh active Pending
- 2012-05-25 PH PH1/2013/502442A patent/PH12013502442A1/en unknown
- 2012-05-25 US US14/119,902 patent/US20140112953A1/en not_active Abandoned
-
2013
- 2013-11-07 IL IL229307A patent/IL229307A0/en unknown
- 2013-11-26 CO CO13277999A patent/CO6811814A2/es unknown
-
2016
- 2016-08-05 AU AU2016210743A patent/AU2016210743A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA201391515A1 (ru) | 2014-05-30 |
| CA2837145A1 (en) | 2012-11-29 |
| BR112013030236A2 (pt) | 2016-12-06 |
| AU2012260807B2 (en) | 2016-05-12 |
| US20140112953A1 (en) | 2014-04-24 |
| CO6811814A2 (es) | 2013-12-16 |
| MX2013013862A (es) | 2014-01-23 |
| PE20140646A1 (es) | 2014-05-29 |
| AU2016210743A1 (en) | 2016-08-25 |
| CN103619349A (zh) | 2014-03-05 |
| SG194950A1 (en) | 2013-12-30 |
| JP2014515367A (ja) | 2014-06-30 |
| PH12013502442A1 (en) | 2018-03-21 |
| CN107050445A (zh) | 2017-08-18 |
| WO2012160199A1 (en) | 2012-11-29 |
| IL229307A0 (en) | 2014-01-30 |
| EP2714076A1 (en) | 2014-04-09 |
| KR20140033171A (ko) | 2014-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12013502442A1 (en) | Inactivated dengue virus vaccine | |
| MX2022006603A (es) | Vacuna contra el virus de la influenza de amplio espectro. | |
| EP4349404A3 (en) | Respiratory virus vaccines | |
| CY1116835T1 (el) | Νεο ευρωπαϊκο στελεχος toy prrsv | |
| MX2021006342A (es) | Mutantes de virus de influenza y usos para los mismos. | |
| PH12018501602A1 (en) | Subunit immersion vaccines for fish | |
| MD4589B1 (ro) | Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C | |
| PH12016500486A1 (en) | Aza-pyridone compounds and uses thereof | |
| PH12015501482B1 (en) | Nasal influenza vaccine composition | |
| AU2015296298A8 (en) | Flagellin-based agents and uses including effective vaccination | |
| MX2013008390A (es) | Preparacion de estructuras de metal-triazolato. | |
| MD20140136A2 (ro) | Inhibitori ai virusului hepatic C | |
| MX2013000958A (es) | Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma. | |
| MY197723A (en) | Vaccine compositions for the prevention of dengue virus infection | |
| PH12017501370A1 (en) | Bivalent swine influenza virus vaccine | |
| PH12014502875A1 (en) | Vaccine compositions for prevention against dengue virus infection | |
| PH12015501637A1 (en) | Inactivated dengue virus vaccine with aluminium-free adjuvant | |
| PH12016500500A1 (en) | A viral vaccine and methods of manufacture thereof | |
| MX2013013801A (es) | Oligodesoxinucleotidos inmunoestimuladores. | |
| MX2016014937A (es) | Composiciones para el cuidado bucal que tienen estabilidad mejorada. | |
| MX2014010433A (es) | Nueva forma cristalina de sulfato de sitagliptina. | |
| GB201017519D0 (en) | Vaccines | |
| EP3599247A3 (en) | Recombinant hemagglutinin protein of influenza virus and vaccine containing the same | |
| MX2014001158A (es) | Virus recombinantes de influenza porcina y usos del mismo. | |
| GR20150100035A (el) | Φαρμακευτικο σκευασμα περιεχον απρεπιταντη και μεθοδος παρασκευης αυτου |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |